In addition to their glucose-lowering effect, SGLT2 inhibitors were associated with better kidney outcomes and lower cardiovascular events and all-cause mortality in patients with or without type 2 diabetes mellitus (12-15). This evidence concerns the gene SLC5A2 and diabetes mellitus.